Clinical Trials Logo

Unresectable Esophageal Cancer clinical trials

View clinical trials related to Unresectable Esophageal Cancer.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT04005170 Completed - Clinical trials for Unresectable Esophageal Cancer

Combination of Toripalimab and Chemoradiotherapy in Esophageal Cancer

Start date: June 25, 2019
Phase: Phase 2
Study type: Interventional

Definitive chemoradiotherapy (CRT) is the standard treatment option for unresectable esophageal cancer (EC). However, as high as more than 40% of EC patients experienced locoregional recurrence after concurrent CRT. Immunotherapy targeting the PD-1/PD-L1 checkpoints has demonstrated promising activity in advanced EC. The aim of this study was to evaluate the efficacy and safety of the combination of toripalimab (an anti-PD-1 antibody) combined with definitive CRT in locally advanced esophageal squamous cell carcinoma (ESCC).